A Retrospective Study of Serum Indicators in Functional High-Risk Multiple Myeloma Patients Undertaking Proteasome Inhibitors Treatments

被引：0
|
作者：
Zhan, Linquan [1 ]
Yuan, Dai [1 ]
Ge, Xueling [1 ]
Ding, Mei [1 ]
Zhou, Xiangxiang [1 ]
Wang, Xin [1 ]
机构：
[1] Shandong Prov Hosp, Dept Hematol, Shandong, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-378
引用
收藏
页码：S251 / S251
页数：1
相关论文
共 50 条
  • [1] Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study
    Zhan, Linquan
    Yuan, Dai
    Ge, Xueling
    Ding, Mei
    Wang, Jianhong
    Zhou, Xiangxiang
    Wang, Xin
    HEMATOLOGY, 2024, 29 (01)
  • [2] Genomic characterization of functional high-risk multiple myeloma patients
    Soekojo, Cinnie Yentia
    Chung, Tae-Hoon
    Furqan, Muhammad Shaheryar
    Chng, Wee Joo
    BLOOD CANCER JOURNAL, 2022, 12 (01)
  • [3] Genomic characterization of functional high-risk multiple myeloma patients
    Cinnie Yentia Soekojo
    Tae-Hoon Chung
    Muhammad Shaheryar Furqan
    Wee Joo Chng
    Blood Cancer Journal, 12
  • [4] Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study
    Kim, Kihyun
    Kim, Jin Seok
    Yoon, Sung-Soo
    Yoon, Dok-Hyun
    Eom, HyeonSeok
    Lee, Je-Jung
    Yim, Hyeonwoo
    Park, Misun
    Lee, Hojoon
    Min, Chang Ki
    BLOOD, 2020, 136
  • [5] Identifying the Genomic Profile of Functional High-Risk Multiple Myeloma Patients
    Soekojo, Cinnie Yentia
    Chung, Tae-Hoon
    Furqan, Muhammad Shaheryar
    Chng, Wee-Joo
    BLOOD, 2020, 136
  • [6] CLINICAL FEATURES OF HIGH-RISK MULTIPLE MYELOMA: A SINGLE CENTRE RETROSPECTIVE STUDY
    Curci, P.
    Giordano, A.
    Rizzi, R.
    Delia, M.
    Spinosa, C.
    Leo, M.
    Nardelli, G.
    Lerario, G.
    Specchia, G.
    HAEMATOLOGICA, 2012, 97 : 619 - 619
  • [7] Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients
    Byun, Ja Min
    Shin, Dong-Yeop
    Hong, Junshik
    Kim, Inho
    Kim, Hyun Kyung
    Lee, Dong Soon
    Koh, Youngil
    Yoon, Sung-Soo
    CANCER MEDICINE, 2018, 7 (03): : 831 - 841
  • [8] Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients
    Dervan, Andrew P.
    Mason, Michael
    Towfic, Fadi
    Amatangelo, Michael
    Auclair, Daniel
    Bassett, Douglas
    Dai, Hongyue
    Dalton, William S.
    Danziger, Samuel
    Flynt, Erin
    Goldschmidt, Hartmut
    Guinney, Justin
    Hose, Dirk
    Mavrommatis, Konstantimos
    Morgan, Gareth J.
    Munshi, Nikhil
    Ratushny, Alexander
    Rozelle, Dan
    Samur, Mehmet Kemal
    Schmitz, Frank
    Shain, Kenneth H.
    Trotter, Matthew
    Walker, Brian A.
    White, Brian S.
    Yu, Thomas
    Thakurta, Anjan
    BLOOD, 2017, 130
  • [9] Clinical Feature and Predictive Model for Transplanted Patients with Functional High-Risk Multiple Myeloma
    Yu, Tongyong
    Li, Juan
    BLOOD, 2024, 144 : 4727 - 4727
  • [10] Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
    Nahi, Hareth
    Vatsveen, Thea Kristin
    Lund, Johan
    Heeg, Bart M. S.
    Preiss, Birgitte
    Alici, Evren
    Moller, Michael Boe
    Wader, Karin Fahl
    Moller, Hanne E. H.
    Groseth, Lill Anny
    Ostergaard, Brian
    Dai, Hong Yan
    Holmberg, Erik
    Gahrton, Gosta
    Waage, Anders
    Abildgaard, Niels
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (01) : 46 - 54
12345